Amyris (NASDAQ:AMRS) and Strattner Financial Group (OTCMKTS:SCNG) are both small-cap basic materials companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.
Valuation and Earnings
This table compares Amyris and Strattner Financial Group’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Amyris||$152.56 million||9.68||-$242.77 million||($2.72)||-2.27|
|Strattner Financial Group||N/A||N/A||N/A||N/A||N/A|
This table compares Amyris and Strattner Financial Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Strattner Financial Group||N/A||N/A||N/A|
Institutional & Insider Ownership
36.1% of Amyris shares are held by institutional investors. 47.4% of Amyris shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Amyris has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Strattner Financial Group has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Amyris and Strattner Financial Group, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Strattner Financial Group||0||0||0||0||N/A|
Amyris presently has a consensus target price of $5.78, indicating a potential downside of 6.34%. Given Amyris’ higher possible upside, research analysts plainly believe Amyris is more favorable than Strattner Financial Group.
Amyris beats Strattner Financial Group on 5 of the 8 factors compared between the two stocks.
Amyris, Inc., a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company's technology platform enables to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. It applies technology platform to engineer, manufacture, and sell products for the clean health and beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
About Strattner Financial Group
Strattner Financial Group Corp., an investment management company, manages multiple alternative asset classes, including private equity, convertibles, credit, and hedge funds. It also focuses on selling satellite based communications devices. The company was formerly known as SC Holdings Corp. and changed its name to Strattner Financial Group Corp. in March 2020. The company was founded in 2012 and is headquartered in Tsim Sha Tsui, Hong Kong.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.